AU2004258070B2 - Inhibition of apoptosis-specific elF-5A ("elF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics - Google Patents

Inhibition of apoptosis-specific elF-5A ("elF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics Download PDF

Info

Publication number
AU2004258070B2
AU2004258070B2 AU2004258070A AU2004258070A AU2004258070B2 AU 2004258070 B2 AU2004258070 B2 AU 2004258070B2 AU 2004258070 A AU2004258070 A AU 2004258070A AU 2004258070 A AU2004258070 A AU 2004258070A AU 2004258070 B2 AU2004258070 B2 AU 2004258070B2
Authority
AU
Australia
Prior art keywords
apoptosis
cells
cell
seq
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004258070A
Other languages
English (en)
Other versions
AU2004258070A1 (en
Inventor
Adrienne Boone
Dominic Cliche`
Charles Dinarello
Bruce C. Galton
Marianne Hopkins
Benjamin Pomerantz
Leonid Reznikov
Catherine Taylor
John E. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eloxx Pharmaceuticals Inc
Original Assignee
Senesco Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc
Publication of AU2004258070A1 publication Critical patent/AU2004258070A1/en
Application granted granted Critical
Publication of AU2004258070B2 publication Critical patent/AU2004258070B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2004258070A 2003-06-06 2004-06-07 Inhibition of apoptosis-specific elF-5A ("elF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics Ceased AU2004258070B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US47619403P 2003-06-06 2003-06-06
US60/476,194 2003-06-06
US50473103P 2003-09-22 2003-09-22
US60/504,731 2003-09-22
US52824903P 2003-12-10 2003-12-10
US60/528,249 2003-12-10
US55767104P 2004-03-31 2004-03-31
US60/557,671 2004-03-31
US57581404P 2004-06-02 2004-06-02
US60/575,814 2004-06-02
PCT/US2004/018012 WO2005007853A2 (fr) 2003-06-06 2004-06-07 Inhibition d'eif-5a specifique de l'apoptose ('eif-5a1') au moyen d'oligonucleotides antisens et de petits arn interferents utilises comme agents therapeutiques anti-inflammatoires

Publications (2)

Publication Number Publication Date
AU2004258070A1 AU2004258070A1 (en) 2005-01-27
AU2004258070B2 true AU2004258070B2 (en) 2008-12-11

Family

ID=34084831

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004258070A Ceased AU2004258070B2 (en) 2003-06-06 2004-06-07 Inhibition of apoptosis-specific elF-5A ("elF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics

Country Status (9)

Country Link
EP (1) EP1636364A2 (fr)
JP (1) JP5666074B2 (fr)
KR (1) KR20060013428A (fr)
AU (1) AU2004258070B2 (fr)
CA (1) CA2528372A1 (fr)
IL (1) IL172365A0 (fr)
NZ (2) NZ544159A (fr)
TW (1) TW200512293A (fr)
WO (1) WO2005007853A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381708B2 (en) 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
EP1601767B1 (fr) 2003-03-05 2012-04-25 Senesco Technologies, Inc. Utilisation de siarn pour supprimer l'expression de eif-5a1 dans le traitement du glaucome
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
US20140371299A1 (en) * 2004-06-07 2014-12-18 Senesco Technologies, Inc. Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
EP1769075A2 (fr) * 2004-07-20 2007-04-04 Senesco Technologies, Inc. Utilisation d'arnsi eif-5a specifiques de l'apoptose et de polynucleotides antisens pour inhiber/supprimer une reponse inflammatoire
NZ556236A (en) * 2004-12-03 2009-12-24 Senesco Technologies Inc Apoptosis-specific eIF-5A and polynucleotides encoding same
WO2007070824A2 (fr) * 2005-12-13 2007-06-21 Senesco Technologies, Inc. Utilisation d'eif-5a pour detruire les cellules d'un myelome multiple
EP1996707A2 (fr) * 2006-03-20 2008-12-03 Senesco Technologies, Inc. Nouvelle méthode pour la protection d'îlots de langerhans de l'apoptose au cours du processus de prélèvement chez un donneur
KR20080082688A (ko) * 2006-03-20 2008-09-11 세네스코 테크놀로지스 인코포레이티드 공여자의 섬 세포 채취 과정 동안에 섬 세포를아폽토시스로부터 보호하는 신규 방법
KR20080070879A (ko) * 2006-03-20 2008-07-31 세네스코 테크놀로지스 인코포레이티드 패혈증 또는 출혈성 쇼크를 치료하기 위한 ｅＩＦ-5Ａ1ｓｉＲＮＡ 및 안티센스의 용도
WO2007115047A2 (fr) * 2006-03-29 2007-10-11 Senesco Technologies, Inc. INHIBITION DE LA RÉPLICATION DU VIH ET DE L'EXPRESSION DE p24 PAR LE BIAIS D'elF-5
US20090093434A1 (en) * 2007-08-20 2009-04-09 Senesco Technologies, Inc. Use of eif-5a1 sirna to protect islets cells from apoptosis and to preserve their functionality
CN102282259A (zh) 2008-03-07 2011-12-14 森尼斯科技术公司 与有义构建体实现期望多核苷酸的表达的用途相组合的、sirna实现内源基因的减量调节的用途
WO2009144933A1 (fr) * 2008-05-27 2009-12-03 国立大学法人東京大学 Inducteur de l'apoptose
US8445638B2 (en) 2008-09-03 2013-05-21 Senesco Technologies, Inc. Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010286A2 (fr) * 2001-07-23 2003-02-06 Senesco, Inc. Acides nucleiques, polypeptides et methodes permettant de moduler une apoptose
US20030050272A1 (en) * 2001-07-23 2003-03-13 Catherine Taylor Nucleic acids, polypeptides, and methods for modulating apoptosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1173897A (zh) * 1995-02-13 1998-02-18 诺瓦蒂斯有限公司 真核起始因子5A(eIF－5A)突变体
CA2448320A1 (fr) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Modulation a base de l'acide nucleique des maladies et troubles de l'appareil reproducteur chez la femme
US7381708B2 (en) * 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
DK2280070T3 (en) * 2001-07-23 2015-08-24 Univ Leland Stanford Junior Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals
EP1601767B1 (fr) * 2003-03-05 2012-04-25 Senesco Technologies, Inc. Utilisation de siarn pour supprimer l'expression de eif-5a1 dans le traitement du glaucome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010286A2 (fr) * 2001-07-23 2003-02-06 Senesco, Inc. Acides nucleiques, polypeptides et methodes permettant de moduler une apoptose
US20030050272A1 (en) * 2001-07-23 2003-03-13 Catherine Taylor Nucleic acids, polypeptides, and methods for modulating apoptosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FASEB Journal 2002 16(4): A162 *

Also Published As

Publication number Publication date
JP2006526989A (ja) 2006-11-30
AU2004258070A1 (en) 2005-01-27
JP5666074B2 (ja) 2015-02-12
IL172365A0 (en) 2006-04-10
NZ574973A (en) 2010-10-29
TW200512293A (en) 2005-04-01
CA2528372A1 (fr) 2005-01-27
WO2005007853A2 (fr) 2005-01-27
NZ544159A (en) 2009-04-30
EP1636364A2 (fr) 2006-03-22
KR20060013428A (ko) 2006-02-09
WO2005007853A3 (fr) 2005-10-27

Similar Documents

Publication Publication Date Title
US8754057B2 (en) Inhibition of apoptosis-specific eIF-5A(eIF-5A1″) with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics
AU2004258070B2 (en) Inhibition of apoptosis-specific elF-5A ("elF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics
EP1959010A2 (fr) Eif-5A spécifique de l'apoptose et polynucléotides codant pour un tel facteur
US20060287265A1 (en) Apoptosis-specific eIF-5A and polynucleotides encoding same
AU2005269647B2 (en) Use of apoptosis-specific eIF-5A siRNAs and antisense polynucleotides to inhibit/suppress an inflammatory response
JP5566250B2 (ja) ｅＩＦ−５Ａ１の発現を抑制するための、アンチセンス・オリゴヌクレオチド又はｓｉＲＮＡの使用
KR20070018146A (ko) 염증 반응을 저해/억제하기 위한 아폽토시스-특이적ｅＩＦ-5Ａ ｓｉＲＮＡ 및 안티센스 폴리뉴클레오타이드의이용

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD CO-INVENTORS GALTON, BRUCE C. AND DINARELLO, CHARLES AND REZNIKOV, LEONID AND BOONE, ADRIENNE AND HOPKINS, MARIANNE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD CO-INVENTORS CLICHE`, DOMINIC AND POMERANTZ, BENJAMIN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 07 JUN 2009 TO 07 FEB 2010 IN WHICH TO PAY A RENEWAL FEE HASBEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 07 FEB 2010.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired